Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Chamberlain

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Journal of Medicinal Chemistry|July 31, 2008
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitorsJingshan Ren, Philip P Chamberlain, Anna Stamp, et al.
Blood|January 14, 2021
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myelomaSarah Gooding, Naser Ansari-Pour, Fadi Towfic, et al.
Nature Communications|September 2, 2021
Structure of the human marker of self 5-transmembrane receptor CD47Gustavo Fenalti, Nicolas Villanueva, Mark Griffith, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 31, 2011
Transgenic animal models in toxicology: historical perspectives and future outlookDarrell R Boverhof, Mark P Chamberlain, Clifford R Elcombe, et al.
Journal of Medicinal Chemistry|April 21, 2017
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and AiolosMary E Matyskiela, Weihong Zhang, Hon-Wah Man, et al.
Nature Structural & Molecular Biology|August 11, 2014
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogsPhilip P Chamberlain, Antonia Lopez-Girona, Karen Miller, et al.
Nature Chemical Biology|September 8, 2018
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrateMary E Matyskiela, Suzana Couto, Xinde Zheng, et al.
Biologicals : Journal of the International Association of Biological Standardization|March 1, 2011
Taking immunogenicity assessment of therapeutic proteins to the next levelI C Büttel, P Chamberlain, Y Chowers, et al.
Nature|July 2, 2015
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDSJan Krönke, Emma C Fink, Paul W Hollenbach, et al.
Nature|June 25, 2016
A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligaseMary E Matyskiela, Gang Lu, Takumi Ito, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Journal of Medicinal Chemistry|July 31, 2008
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitorsJingshan Ren, Philip P Chamberlain, Anna Stamp, et al.
Blood|January 14, 2021
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myelomaSarah Gooding, Naser Ansari-Pour, Fadi Towfic, et al.
Nature Communications|September 2, 2021
Structure of the human marker of self 5-transmembrane receptor CD47Gustavo Fenalti, Nicolas Villanueva, Mark Griffith, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 31, 2011
Transgenic animal models in toxicology: historical perspectives and future outlookDarrell R Boverhof, Mark P Chamberlain, Clifford R Elcombe, et al.
Journal of Medicinal Chemistry|April 21, 2017
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and AiolosMary E Matyskiela, Weihong Zhang, Hon-Wah Man, et al.
Nature Structural & Molecular Biology|August 11, 2014
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogsPhilip P Chamberlain, Antonia Lopez-Girona, Karen Miller, et al.
Nature Chemical Biology|September 8, 2018
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrateMary E Matyskiela, Suzana Couto, Xinde Zheng, et al.
Biologicals : Journal of the International Association of Biological Standardization|March 1, 2011
Taking immunogenicity assessment of therapeutic proteins to the next levelI C Büttel, P Chamberlain, Y Chowers, et al.
Nature|July 2, 2015
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDSJan Krönke, Emma C Fink, Paul W Hollenbach, et al.
Nature|June 25, 2016
A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligaseMary E Matyskiela, Gang Lu, Takumi Ito, et al.
Pageof 14